Program Schedule

Wednesday, March 15, 2017

8:00am – 8:30am

Coffee & Light Breakfast

8:30am – 9:00am

President’s Welcome
Martha Morrell, MD, President


9:00am – 12:00pm

Pipeline Presentations Part 1

  • Brief presentations on therapies in early phases of development.
  • Scientists/Sponsoring Companies seeking input on applications, development plans, regulatory pathways and funding.

Kathleen Clarence-Smith, MD, PhD,
Chase Pharmaceuticals (Chair)

*All Day*- Course in Translational Research
(view separate agenda)

Steven Schachter, MD,
Harvard Medical School  (Co-Chair)

Stewart Factor, MD,
Emory University (Co-Chair)

12:00pm – 2:00pm

Lunch with Pipeline and Poster Presenters

2:00pm – 5:00pm

Pipeline Presentations Continue Part 2

Kathleen Clarence-Smith, MD, PhD,
Chase Pharmaceuticals (Chair)

Course in Translational Research
(view separate agenda)

Steven Schachter, MD,
Harvard Medical School  (Co-Chair)

Stewart Factor, MD,
Emory University (Co-Chair)

3:30pm – 3:45pm


5:00pm – 6:00pm

Opening Reception (all)

6:00pm – 8:30pm Careers in Neuroscience Dinner (all)
Martha Morrell, MD, President


Steven Schachter, MD

Professor of Neurology, Harvard Medical School


Alfred Sandrock, MD, PhD

CMO, EVP Neurology Discovery and Development, Biogen

Drug and Biologic Therapies

Michael DeMane, MS

Executive Chairman, Nevro Corp

Device Therapies

Carlos Pena, PhD

Director, Division of Neurological and Physical Medicine Devices, CDRH


William Marks, MD

Head of Clinical Neurology, Verily Life Sciences

Technology and Data Science

Jacob Vogelstein, PhD

IARPA and Camden Partners

Federal Intelligence Agency Research/Venture Capital

Thursday, March 16, 2017




8:00am – 8:30am

Coffee & Breakfast

8:30am – 12:00pm Opening Plenary: Alzheimer Disease: Therapeutic Horizon or Mirage

Robert W. Hamill, MD,
University of Vermont (Co-Chair)

Steven T. DeKosky MD,
McKnight Brain Institute (Co-Chair)

Challenges in Delaying / Preventing Alzheimer Disease Walter Koroshetz, MD, NINDS
Expanding the Dimensions of AD Research: New Targets and Goals

Eliezer Masliah, MD, National Institutes of Aging, NIH

Challenging Issues in Developing Disease Modifying Therapy in Alzheimer Disease

Eric R. Siemers, MD, Eli Lilly and Company

Patient Participation in Trial Design: Recruitment and Retention of an “Invested” Population

Mary Sano, PhD, Icahn School of Medicine at Mount Sinai

Biomarkers in Alzheimer Disease Leslie M. Shaw, PhD, Univ. of Pennsylvania
Challenges of, and Strategies for, Testing the Amyloid Hypothesis in Alzheimer Disease Alfred W. Sandrock Jr., MD, PhD, Biogen Inc.

12:00pm – 1:30pm

Lunch with Pipeline and Poster Presenters

1:30pm – 3:00pm Plenary session – Hot Topics: Big Data and Neurotherapeutics William Marks Jr., MD, Verily (Chair)
Application of Big Data to Neurotherapeutics  William Marks Jr., MD, Verily
Large Scale Modeling: Identifying Neural Connections and Circuits Costas Anastassiou PhD, Allen Institute for Brain Science
Aggregating Data from Patient Networks: Understanding the Patient Experience Paul Cannon, PhD, 23andMe

3:00pm – 3:15pm


3:15pm – 5:15pm Plenary Session: Pharmacogenomics for CNS Medication Discovery, Development and Prescribing

C. Anthony Altar, PhD, NeuroDrug Consulting. (Chair)

Research, Development, and Application of a SNP-based Psychiatric Pharmacogenomic Product: Clinical and Economic Benefits C. Anthony Altar, PhD, NeuroDrug Consulting
Using Pharmacogenomics for CNS Target Identification Todd Lencz, PhD, Feinstein Institute for Medical Research
Genetic Enrichment Strategy in an Alzheimer’s Disease Prevention Scott Sundseth, PhD, Cabernet Pharmaceuticals
Future Innovations to the Use of Genetics in Prescribing CNS Medication Falk W. Lohoff, MD, NIAAA

6:00pm – 8:30pm

Dinner Symposium

Art, Music, Poetry and the Brain 

Victor Krauthamer, PhD, FDA(Chair)

Dr Jose “Pepe” Contreras-Vidal, Univ. of Houston

Friday, March 17, 2017




8:00am – 8:30am

Coffee & Breakfast

8:30am – 9:00am

ASENT Business Meeting

Martha Morrell, MD, President

9:00am – 12:00pm Concurrent Symposium: Neuromodulation Update: Implantable Devices to Treat Disease/Disorders of the Central and Autonomic Nervous Systems

Mike Wolfson, PhD, NIH (Co-Chair)

Kip Ludwig, PhD, Mayo Clinic (Co-Chair)

10:30am – 10:45am
Neuromodulation at the FDA: Communication Across Divisions and New Developments Carlos Peña, PhD, FDA
The Stentrode – A Minimally Invasive Option for Neuromodulation Therapies in the Brain

J. Mocco, MD, PhD, Mount Sinai Health System

Bioelectronic Medicines – Injectable, Wireless Systems for Autonomic Nervous System Neuromodulation Roy Katso, PhD, Glaxo, Smith, Kline
Tapping the Spinal Cord, Rootlets, and Ganglia  Doug Webber, PhD, DARPA
9:00a m – 12:00pm Concurrent Symposium: Pharmacologic Innovations and Drug Repurposing

Karoly Nikolich, PhD, Alkahest (Co-Chair)

Kathleen Clarence-Smith, MD, PhD , Chase Pharmaceuticals (Chair)

10:30am – 10:45am

Use of Meta-Structures for Leads on Repurposing Drugs for New Indications

Robert Konrat, PhD, University of Vienna

Repurposing in Pharmaceutical Research and Development 

Frank Dullweber, PhD, Boehringer Ingelheim

Regulatory Pathway for Repurposed Drugs

Kurt R. Karst, Hyman, Phelps & McNamara, PC

Nilotinib Effects in Parkinson’s Disease & Dementia w/Lewy Bodies  Charbel Moussa, MD, PhD, Georgetown University
CPC-201 for Alzheimer’s Disease  Kathleen Clarence-Smith, MD, PhD, Chase Pharmaceuticals
Novel Therapeutic Against Nerve Agent-Induced Seizures and Brain Damage 

Maria Braga, DDS, PhD, Uniformed Services University

12:00pm – 1:30pm

Lunch with Posters and Authors

1:30pm – 3:00pm

Concurrent Symposium – Hot Topics: Neurodegeneration: Parkinson’s Disease in 2017. What is Really New?

Stanley Fahn, MD, Honoree, NY Presbyterian (Co-Chair)
Bennett Lavenstein, MD, Children’s Nat’l Health System (Co-Chair)

Introduction Stanley Fahn, MD, NY Presbyterian
Biomarkers in Parkinson’s Disease

David Standaert, MD, PhD, University of Alabama at Birmingham

Molecular Genetics Targets Therapeutics in Parkinson’s Disease Ted Dawson, MD, PhD, John Hopkins Hospital
Neuromodulatory Advances in Parkinson’s Disease  Christopher Hess, MD, University of Florida
1:30pm – 3:00pm Concurrent Session – Hot Topics: Therapeutics in Psychiatry and Rapidly Acting Antidepressants Christopher C. Gallen, MD, PhD, Wex Phamaceuticals (Chair)
Clinical Trial Considerations Pertinent to Demonstrating Improved Speed of Clinical Improvement with Novel Agents for Depression 
Christopher C. Gallen, MD, PhD, Wex Phamaceuticals
Ketamine Metabolism to 6–Hydroxynorketamines: Pharmacology Underlying Rapid Antidepressant Action Todd Gould, MD, Univ. of Maryland School of Medicine
Rapastinel: An NMDA Receptor Modulator with Rapid Acting and Long Lasting Antidepressant Activity

Joseph Moskal, PhD, Northwestern University

Targeting the GABAergic System for the Rapid Treatment of Depression Adam Van Dyke, Asulon Therapeutics, Inc

3:00pm – 3:15pm


3:15pm – 5:00pm


Closing Plenary: The Placebo Effect: Causes and Corrections for Clinical Trials Amy Chappell, MD, Independent Expert Consultant (Chair)
The Biological Basis of the Placebo Response

Howard Fields, MD, PhD, UCSF

The Placebo Response in Psychiatry

William Potter, MD, PhD, NIH

Placebo Response from a Regulatory Perspective Josephine Briggs, MD, NCCIH
The Placebo Response in Epilepsy

Jacqueline French, MD, NYU Langone Medical Center